Prednisone

Limits on what this shows

• Key negative/null findings: None identified; the class-level animal/in vitro literature is unusually consistent in direction.
• At-risk subgroups: Patients on high-dose or prolonged glucocorticoid therapy where muscle atrophy is clinically evident; extrapolated from dexamethasone models, not confirmed for prednisone directly.
• Counter-evidence: Dexamethasone is a distinct molecule from prednisone (cohort test fails for the primary mechanistic studies); the DMD human data uses "glucocorticoid" as a class descriptor without confirming which specific drug in the retrievable snippet.

Population evidence

Multiple in vitro/animal studies using dexamethasone document mitochondrial dysfunction in skeletal muscle: "Mitochondrial Dysfunction Launches Dexamethasone-Induced Skeletal Muscle Atrophy via AMPK/FOXO3 Signaling" (PMID 26592738, 2016); "Dihydromyricetin Attenuates Dexamethasone-Induced Muscle Atrophy by Improving Mitochondrial Function via the PGC-1alpha Pathway" (PMID 30165349, 2018); further supporting studies examined mitochondrial biogenesis and myotube growth in glucocorticoid-injured muscle cells (PMID 35059739, 2022; PMID 33649814, 2021). In Duchenne muscular dystrophy patients treated with glucocorticoids (a class in which prednisone/prednisolone is a standard agent), mitochondrial-dysfunction-associated microRNA (miR-379) normalization was reported with treatment (PMID 34533019, 2021).

Mechanism

Glucocorticoid receptor activation triggers AMPK/FOXO3 signaling and disrupts PGC-1alpha-driven mitochondrial biogenesis in skeletal muscle, consistently reproduced across several independent dexamethasone model systems.

Counter-evidence held on record

This is class extrapolation from dexamethasone, a related but distinct glucocorticoid; the mechanism is plausible for prednisone given shared glucocorticoid receptor pharmacology, but no prednisone-specific mitochondrial study was located.

Limits on what this shows

• Key negative/null findings: The VEXAS case shows decreased oxidative stress after starting prednisone, which most plausibly reflects successful treatment of the underlying inflammatory disease (confounding by indication) rather than an antioxidant property of prednisone itself; it is recorded as counter-evidence against a simple "prednisone increases oxidative stress" narrative.
• At-risk subgroups: Not established for a general human population; the clearest quantified effect is in a non-mammalian model.
• Counter-evidence: Human data are either reverse-direction (VEXAS, confounded by disease treatment) or confounded by co-administered drugs (transplant polytherapy); direction of net effect in humans on prednisone monotherapy is not established by this review.

Population evidence

In tadpoles, prednisone exposure caused oxidative stress evidenced by increased malondialdehyde and carbonyl protein levels, alongside altered catalase and glutathione peroxidase activity (PMID 38387247, 2024) — a direct, prednisone-specific, quantified animal finding. In a VEXAS syndrome case, oxidative stress levels decreased after oral prednisone plus tocilizumab treatment (PMID 36544501, 2022), a reverse-direction finding. In kidney transplant patients on a combined tacrolimus, mycophenolate mofetil, and prednisone regimen, thiobarbituric acid-reactive substances (TBARS) were examined as an oxidative stress marker (PMID 24101297, 2014), but the effect cannot be isolated to prednisone given the polytherapy.

Mechanism

Glucocorticoid-driven metabolic and redox shifts increasing lipid peroxidation products (malondialdehyde) and protein oxidation (carbonyl proteins) in the tadpole model; no distinct mechanism was detailed for the discordant human findings.

Counter-evidence held on record

The only clean, drug-specific, quantified signal is a non-mammalian animal study; human evidence is genuinely mixed and confounded, so this is graded yellow with an explicit note that net direction in humans is unresolved, not silently assumed to be "increased stress."

Limits on what this shows

• Key negative/null findings: In the rheumatoid arthritis study, methotrexate (not corticosteroid) was the treatment shown to elevate zinc; this is useful counter-evidence against assuming any RA-treatment-associated trace metal change is automatically attributable to corticosteroid.
• At-risk subgroups: Not established for prednisone specifically.
• Counter-evidence: Dexamethasone is not prednisone (cohort test fails for this drug); this is class extrapolation per Tier C rules, capped at yellow.

Population evidence

A study examined the association between dexamethasone treatment and altered serum trace metal concentrations in patients receiving cisplatin-based chemotherapy (PMID 32393433, Pharmazie 2020). A rheumatoid arthritis study examined the effects of different medical treatments on serum copper, selenium, and zinc, reporting that methotrexate elevated zinc but not selenium (PMID 20798997); the corticosteroid arm's effect on copper specifically could not be confirmed from the retrievable snippet.

Mechanism

Not detailed in retrievable material; class extrapolation from dexamethasone (same glucocorticoid receptor mechanism family) to prednisone is plausible but unconfirmed for copper specifically.

Counter-evidence held on record

No prednisone-specific copper study was located despite multi-phrasing searches; this entry rests entirely on class-level (dexamethasone) and unconfirmed-drug human data.

Limits on what this shows

• Key negative/null findings: No study in this review measured prednisone lowering iron, ferritin, or transferrin saturation in a standard (non-anemia-therapy) population; a search for prednisone-specific iron deficiency literature found only incidental co-occurrence in patients with unrelated causes of anemia, not a causal drug effect.
• At-risk subgroups: Not a depletion risk group; the "at-risk" framing does not apply in the usual sense. Patients with GI adverse effects of chronic corticosteroid therapy (peptic ulcer, GI bleeding, listed in the label) could theoretically lose iron via occult blood loss, but this would be an outcome of the bleeding risk, not a direct nutrient-depletion mechanism, and was not directly studied here.
• Counter-evidence: The disease-specific therapeutic-use evidence (Diamond-Blackfan anemia, TMPRSS6-mutation IRIDA) does not generalize to the average prednisone patient taking the drug for an unrelated indication; this is a mechanism/pharmacology finding, not a population-wide iron-status effect.

Population evidence

A 2026 study describes CD163-positive macrophages coordinating erythroblastic island formation and iron metabolism to enable glucocorticoid-induced erythropoiesis, noting glucocorticoids are used to treat erythropoietin-resistant anemias and that glucocorticoid therapy "restores iron metabolism" in that context (PMID 42365354). A case report describes a patient with iron-refractory iron deficiency anemia (a TMPRSS6 mutation disorder) who responded to glucocorticoid treatment (PMID 24661031). Glucocorticoids, with prednisone as a standard first-line agent, are established therapy for Diamond-Blackfan anemia, a red-cell aplasia (PMID 35163808).

Mechanism

Glucocorticoid receptor activation on erythroid progenitors promotes burst-forming-unit erythroid (BFU-E) self-renewal and expansion (also supported by PPAR-alpha/glucocorticoid receptor synergy data, PMID 25970251), which secondarily engages iron-handling machinery to support increased red cell production.

Counter-evidence held on record

This is a reverse-direction, mechanism-level finding (stimulatory, not depleting) confined mainly to specific anemia-treatment contexts. It must never be read as license to expect prednisone to "boost" iron status in ordinary use, and it is not evidence for iron supplementation (Hard Rule 5 framing).

Limits on what this shows

• Key negative/null findings: None identified specific to prednisone; the animal literature is consistently positive for a dysbiosis effect.
• At-risk subgroups: Long-term or high-dose prednisone users, and patients with underlying autoimmune/inflammatory GI disease where baseline dysbiosis may already be present, confounding attribution to the drug alone.
• Counter-evidence: Disease activity itself (lupus, autoimmune pancreatitis, DMD) independently alters the gut microbiome, so human disease-cohort findings are confounded by indication; the cleanest evidence is the rat study, which is Tier B (animal), capping the grade at yellow regardless of how drug-specific it is.

Population evidence

"Long-term prednisone treatment causes fungal microbiota dysbiosis and alters the ecological interaction between gut mycobiome and bacteriome in rats" (PMID 37342562, 2023), a prednisone-specific animal study. In MRL/lpr lupus mice, prednisone was used to treat animals with differing baseline gut microbiota composition, with microbiome outcomes tracked (PMID 32346376, 2020). A study of vincristine and prednisolone chemotherapy in dogs assessed impacts on canine gut microbiota (PMID 40326149, 2025). A narrative review on the gut-muscle axis in Duchenne muscular dystrophy states "prednisone drives gut dysbiosis, inducing a pro-inflammatory phenotype and leaky gut barrier" (PMID 37269541, 2023). A 2026 human study of type 1 autoimmune pancreatitis examined gut microbiota changes following corticosteroid treatment (PMID 42143007); the specific corticosteroid used was not confirmed from the retrievable snippet, though prednisone is the conventional first-line agent for this disease.

Mechanism

Proposed mechanisms include glucocorticoid-driven increases in intestinal permeability ("leaky gut") and immune-mediated shifts in the balance between gut bacterial and fungal populations.

Counter-evidence held on record

Evidence is genuinely drug-specific and consistent across an animal model, a companion-animal clinical study, and a review naming prednisone directly, but remains Tier B without a confirmed human Tier A source, which is why this stays yellow rather than orange.

Limits on what this shows

• Key negative/null findings: No study in this review found prednisone lowering hemoglobin, hematocrit, or oxygen delivery in a standard population; a direct search for "prednisone hemoglobin hematocrit erythropoiesis" returned zero results, and broader searches surfaced only the stimulatory mechanism.
• At-risk subgroups: Not a deficiency-risk group. This mechanism is clinically exploited in specific anemias; it does not indicate that typical prednisone patients experience improved oxygen delivery, since the anemia-specific studies involve a diseased erythroid compartment being pharmacologically rescued.
• Counter-evidence: This is disease-context-specific pharmacology, not a general population finding; it must not be read as evidence that prednisone improves oxygen delivery in patients without an underlying erythroid disorder.

Population evidence

Glucocorticoid-induced erythropoiesis is described mechanistically via CD163-positive macrophages coordinating erythroblastic island formation (PMID 42365354, 2026), with glucocorticoids noted as therapy for erythropoietin-resistant anemias. Corticosteroids, with prednisone as first-line, are established therapy for Diamond-Blackfan anemia, a congenital red-cell aplasia (PMID 35163808, 2022). Erythroid progenitor self-renewal via glucocorticoid receptor and PPAR-alpha synergy is documented mechanistically (PMID 25970251, 2015).

Mechanism

Glucocorticoid receptor signaling in erythroid progenitors promotes burst-forming-unit erythroid (BFU-E) self-renewal, expanding the progenitor pool and increasing red cell output under stress or therapeutic glucocorticoid exposure.

Counter-evidence held on record

This is the drug's own pharmacologic mechanism in specific disease contexts, not a nutrient-style oxygen-delivery deficiency, and not evidence that supplementation or the drug itself should be used to "improve" oxygen delivery outside those specific, physician-directed indications (Hard Rule 2 and Hard Rule 5 framing).

Limits on what this shows

• Key negative/null findings: None identified in the dexamethasone literature; all located studies show reduced ATP content with glucocorticoid exposure and improvement with the tested countermeasure.
• At-risk subgroups: Same as mitochondrial burden: high-dose or prolonged glucocorticoid therapy with clinically evident myopathy.
• Counter-evidence: Dexamethasone, not prednisone, is the study drug (cohort test fails); ATP content was not directly measured in any prednisone-specific source located in this review.

Population evidence

"Qigu capsule alleviates dexamethasone-induced muscle dysfunction through mitochondrial biogenesis," assessing mitochondrial ultrastructure, respiratory chain complex V activity, and ATP content (PMID 40810219, 2025), directly measuring ATP as an endpoint reduced by dexamethasone and improved by the intervention. "Myricanol rescues dexamethasone-induced muscle dysfunction via a sirtuin 1-dependent mechanism" (PMID 30793539, 2019) is part of the same class-level literature base.

Mechanism

Impaired mitochondrial respiratory chain complex V (ATP synthase) activity secondary to glucocorticoid-driven mitochondrial biogenesis disruption, directly lowering measured ATP content in skeletal muscle.

Counter-evidence held on record

Graded separately from mitochondrial burden per protocol even though both entries draw on the same dexamethasone muscle-atrophy literature base (see Overlap Map); this is class extrapolation, not confirmed prednisone-specific human or animal data.